$MDGL announced an upsized $600 million offering consisting of 750K shares and 1.55M pre-funded warrants priced at $260. The pharmaceutical company's move is seen as increasing its acquisition potential. A potential acquirer is interested in the success of $MDGL's drug launch, with the possibility of utilizing a portion of the raised funds post-acquisition. In a separate deal, $AZN is set to pay $2 billion for $FUSN.